Conmed (Conmed) Change In Receivables

: $-47 Mil (TTM As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

Conmed's change in receivables for the quarter that ended in Dec. 2023 was $-9 Mil. It means Conmed's Accounts Receivable increased by $9 Mil from Sep. 2023 to Dec. 2023 .

Conmed's change in receivables for the fiscal year that ended in Dec. 2023 was $-47 Mil. It means Conmed's Accounts Receivable increased by $47 Mil from Dec. 2022 to Dec. 2023 .

Conmed's Accounts Receivable for the quarter that ended in Dec. 2023 was $242 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Conmed's Days Sales Outstanding for the three months ended in Dec. 2023 was 67.60.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Conmed's liquidation value for the three months ended in Dec. 2023 was $-1,101 Mil.

Conmed Change In Receivables Historical Data

The historical data trend for Conmed's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -13.94 [6] => 13.92 [7] => -9.16 [8] => -5.20 [9] => -47.07 )

Conmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-13.94

13.92

-9.16

-5.20

-47.07

Conmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																10.89	-20.67	-14.52	-2.83	-9.05

Conmed Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47 Mil.

Conmed (NYSE:CNMD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Conmed's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	242.279	/	327.045	*	91
=	67.60

2. In Ben Graham's calculation of liquidation value, Conmed's accounts receivable are only considered to be worth 75% of book value:

Conmed's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	24.296	-	1465.799	+	0.75 * 242.279	+	0.5 * 318.324
=	-1,101

Conmed Change In Receivables Related Terms

Thank you for viewing the detailed overview of Conmed's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Conmed (Conmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EC8:Germany

Address

11311 Concept Boulevard, Largo, FL, USA, 33773

Website

https://www.conmed.com

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

Executives

Peters Stanley W Iii	officer: VP GM General Surgery	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner	officer: Executive Vice President & CFO	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford	officer: VP Global Manufacturing	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman	director	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell	officer: Executive Vice President - HR	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon	director	HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Peter K Shagory	officer: EVP,STRAT & CORP DEVT	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Daniel Jonas	officer: Vice President/Legal Affairs, other: General Counsel	C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge	officer: VP Corp. Treasurer	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier	officer: Treasurer and VP, Tax	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Jerome J. Lande	director	1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007
Brent Lalomia	officer: Vice President QA and RA	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John Jed Kennedy	officer: VP GM GI	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Mark E Tryniski	director	C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773
Pat Beyer	officer: President-Conmed International	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773